A 38-year-old male from Mumbai with sputum smear-positive TB is found to have MDR-TB on GeneXpert MTB/RIF. He is started on a standard MDR-TB regimen. Regarding the second-line anti-TB drugs used in MDR-TB treatment, all of the following statements are true EXCEPT:

Explanation

## Second-Line Anti-TB Drugs in MDR-TB Regimens ### WHO-Recommended MDR-TB Drug Classes **Key Point:** MDR-TB treatment requires a combination of second-line drugs selected based on drug susceptibility testing. The newer shorter regimens (20 months) incorporate bedaquiline and fluoroquinolones. | Drug Class | Examples | Mechanism | Role in MDR-TB | |------------|----------|-----------|----------------| | Fluoroquinolones | Levofloxacin, Moxifloxacin | DNA gyrase inhibition (bactericidal) | Backbone drug | | Diarylquinolines | Bedaquiline | ATP synthase inhibition | Newer backbone (shorter regimens) | | Nitroimidazoles | Linezolid | Protein synthesis inhibition | Reserved for XDR-TB | | Thioamides | Ethionamide, Prothionamide | Prodrug activation (multiple targets) | Older second-line | | Injectables | Amikacin, Capreomycin | Protein synthesis inhibition | Intensive phase (4–6 months) | ### Why Option 3 is Incorrect **Clinical Pearl:** Linezolid is **NOT** preferred over ethionamide in routine MDR-TB treatment. The reality is: 1. **Linezolid** — excellent intracellular penetration and CNS penetration, but: - **Higher toxicity**: peripheral neuropathy, optic neuritis, bone marrow suppression (dose-dependent) - **More expensive** than ethionamide - Reserved for **XDR-TB** and difficult-to-treat TB, not routine MDR-TB 2. **Ethionamide** — despite hepatotoxicity and GI side effects, it is: - Preferred in standard MDR-TB regimens due to lower cost and acceptable tolerability - Used in the intensive phase of WHO-recommended shorter MDR-TB regimens **High-Yield:** The statement claims linezolid is "preferred over ethionamide due to better tolerability and lower hepatotoxicity" — this is **factually incorrect**. Linezolid has **greater toxicity** (neuropathy, bone marrow suppression) and is **more hepatotoxic** than ethionamide. Linezolid is reserved for XDR-TB and special circumstances, not routine MDR-TB. ### WHO MDR-TB Shorter Regimen (20 months) ```mermaid flowchart TD A[MDR-TB Diagnosis]:::outcome --> B[Intensive Phase: 4 months]:::action B --> C["Bedaquiline + Levofloxacin + Linezolid + Ethionamide + Pyrazinamide"]:::action C --> D[Continuation Phase: 16 months]:::action D --> E["Levofloxacin + Linezolid + Ethionamide + Pyrazinamide"]:::action E --> F[Treatment Success]:::outcome style A fill:#e8f4f8 style F fill:#e8f4f8 ``` ### Mnemonic: Second-Line Drugs in MDR-TB — "FLY-BEIN" - **F** = Fluoroquinolones (backbone) - **L** = Linezolid (XDR-TB, reserved) - **Y** = (thio)amide: Ethionamide - **B** = Bedaquiline (newer backbone) - **E** = Ethionamide (intensive phase) - **I** = Injectables (amikacin, capreomycin) - **N** = Nitroimidazoles (para-aminosalicylic acid, PAS) ### Monitoring Requirements **Warning:** Linezolid requires: - Monthly FBC (bone marrow suppression) - Baseline and 6-monthly visual acuity (optic neuritis) - Peripheral neuropathy assessment Injectables require: - Baseline and monthly audiometry (ototoxicity) - Baseline and monthly renal function (nephrotoxicity)